SynthesisRadiation oncology (London, England)2025
Technical aspects of SBRT for therapy-refractory ventricular tachycardia: a systematic review for radiation oncologists.
Synthesis in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: A narrative review and pooled analysis of clinical outcomes and treatment delivery approaches.Journal of applied clinical medical physics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentricular tachycardia (VT) is a potentially life-threatening arrhythmia, that can lead to sudden cardiac death. While conventional treatments include antiarrhythmic drugs, catheter ablation, and ICD implantation, recent studies suggest that stereotactic body radiotherapy (SBRT) offers a non-invasive alternative for the treatment of VT. The objective of this systematic review is to summarize the current evidence on SBRT for refractory VT from a radiotherapeutic and technical perspective and to assess its safety and effectiveness.
methodshe systematic search was conducted according to the PRISMA guidelines, using the four databases PubMed, Cochrane, Scopus, and Web of Science. After screening, 15 publications were included and analyzed in this review.
resultsA total of 15 studies were identified in the literature, describing 173 patients. SBRT was delivered as a single fraction using standard LINAC- or CyberKnife-devices with varying isodose prescriptions, motion management, and imaging guidance, highlighting the need for standardized protocols. SBRT consistently reduced VT burden across these studies, with reduction rates ranging from 50 to 99%, and improved quality of life in some patients. However, VT recurrences have also been described.
conclusionDelivery of SBRT for VT is similar to that for malignant diseases but requires specialized imaging and mapping procedures to ensure precise delivery of radiation to small ectopic areas within the beating heart. SBRT seems safe and effective in reducing VT in first clinical trials, though it is not yet a routine treatment. Further controlled trials with standardized treatments and endpoints are needed for confirmation. CLINICAL TRIAL NUMBER: This study does not involve a clinical trial; therefore, a clinical trial number is not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.